Key clinical point: SARS-CoV-2 mRNA vaccine is safe and effective in patients with inflammatory bowel disease (IBD).
Major finding: The immediate adverse reaction after vaccination was rare. Adverse events of special interest (relative risk [RR], 1.15; 95% confidence interval [CI], 0.88-1.51) and new diagnosis of COVID-19 (RR, 0.95; 95% CI, 0.51-1.78) were small and similar between matched IBD and non-IBD cohorts.
Study details: Findings are from a retrospective study of 864,575 patients from multiple institutes across the USA who received the SARS-CoV-2 mRNA vaccine, of which 5,562 patients had a previous diagnosis for IBD. One and 2 vaccine doses were administered in 1,822 and 3,740 patients with IBD, respectively.
Disclosures: The authors declared receiving no financial support or grants for this study. The authors declared no relevant disclosures.
Source: Hadi YB et al. Gastroenterology. 2021 Jun 15. doi: 10.1053/j.gastro.2021.06.014.
